Therapeutic Vaccine Designed To Reduce Recurrence Of Cervical Cancer Under Study | Latest News RSS feed

Therapeutic Vaccine Designed To Reduce Recurrence Of Cervical Cancer Under Study - Latest News


Therapeutic vaccine designed to reduce recurrence of cervical cancer under study

Dr. Sharad A. Ghamande, chief of the Section of Gynecologic Oncology at the Medical College of Georgia and associate director for clinical research at the Georgia Cancer Center at Augusta University. ... read more

Advaxis: First Cancer Vaccine For Cervical Cancer To Be In Pivotal Trial

Advaxis (NASDAQ:ADXS) is a development stage biotechnology company focused on the research, development and commercialization of safe and effective therapeutic cancer vaccines ... recurrent cervical c... read more

The Latest Cancer Research News to Cheer About

Now a trial is studying whether women with ER-positive cancer can safely stop anti-estrogen therapy ... a potential vaccine that would use a woman’s immune system to prevent a recurrence of ovarian ca... read more

Looking for another news?


Inovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer Immunotherapy VGX-3100 in Greater China

VGX-3100 is the world’s first therapeutic vaccine being developed for ... that targets the underlying cause of cervical dysplasia, providing an opportunity for women to reduce their risk of cervical c... read more


Cervical cancer vaccine in early stages

But in some people HPV leads to genital warts and cancers – notably, cervical cancer. The vaccines Gardasil and Cervarix were designed as a prevention for ... lesions that are associated with it. A ne... read more

Inovio's (INO) CEO Joseph Kim on Q1 2018 Results - Earnings Call Transcript

Accordingly, there is the potential to reduce the risk of recurrence ... study of MEDI0457 in the cervical cancer setting. In addition, we're very pleased to report that MedImmune is expanding the tes... read more

Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer

The innovaTV 204 trial is intended to support potential registration under the U.S ... “In a prior study, tisotumab vedotin demonstrated encouraging results in previously treated recurrent and/or meta... read more

Inovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer Immunotherapy VGX-3100 in Greater China

Become a member for free Sign up Sign up read more

Fewer than three doses of cervical cancer vaccine effective

Fewer than three doses of the human papillomavirus (HPV) vaccine Cervarix may be just as effective as the standard three-dose regimen when it comes to preventive measures against cervical cancer, acco... read more

Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer

Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (SGEN) announced today a decision to start a Phase II study of tisotumab vedotin in patients with recurrent ... (HPV) vaccine have had a ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us